Trastuzumab (anti-HER2)

Catalog No.A2007 Purity: 99.94%

Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

Trastuzumab (anti-HER2) Chemical Structure

Click to purchase the isotype control of Trastuzumab (anti-HER2)

Selleck's Trastuzumab (anti-HER2) has been cited by 27 publications

Purity & Quality Control

Batch: Purity: 99.94% Protein concentration: 4.2mg/ml Endotoxin Level: ＜1EU/mg

99.94

Choose Selective HER2 Inhibitors

Biological Activity

Description

Trastuzumab (anti-human HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

Features

Human IgG1

Targets

HER2 ^[1]

In Vitro
In vitro	Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.^[1]
Cell Research:	OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days.

In Vitro

In vitro

Loss of function of CSK or PTEN confers resistance to both lapatinib and trastuzumab in Human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer (GC) cells.^[1]

Cell Research:

OE19 cells transduced with CSK targeting sgRNAs or PTEN targeting sgRNAs were used for following test. OE19 cells transduced with non-targeting sgRNA as control. a Growth curve of test groups with 0.05 μM lapatinib in combination with indicated dose of trastuzumab for 6 days.

In Vivo
In vivo	Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.^[2]
Animal Research	AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models Dosages:10 mg/kg Administration:i.p.^[2]

In Vivo

In vivo

Trastuzumab exerts antitumor effects in ERBB2-positive AFPGC PDX models, in which statistically significant differences are present in the tumor volume between the group treated with AZD5438 combined with trastuzumab and those treated with AZD5438 or trastuzumab alone in ERBB2 and CCNE1 co-amplified PDX models.^[2]

Animal Research

AnimalModels:Female BALB/c nude mice of ERBB2-positive alpha-fetoprotein producing gastric carcinoma patient-derived xenograft models
Dosages:10 mg/kg
Administration:i.p.^[2]

References
[1] Ning G, et al. BMC Cancer. 2021 Aug 16;21(1):923. [2] Lu J, et al. Nat Commun. 2021 Jun 24;12(1):3946.

References

Product Details

CAS No.	180288-69-1
Isotype	Human IgG1
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.